JP Morgan Chase’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
LCM
JP Morgan Chase's STOK Position: Q3 2026 in Review
JP Morgan Chase reduced its Stoke Therapeutics (STOK) stake by 0.84% in Q3 2026, selling an estimated $65.6K and leaving 257,179 shares worth $6.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3219.
JP Morgan Chase first reported a position in STOK in Q3 2019 and has held it in 29 quarters since. The position peaked at $8.82M in Q4 2025. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.
- JP Morgan Chase held 257,179 shares of Stoke Therapeutics worth $6.73M as of Q3 2026.
- JP Morgan Chase sold 2,173 Stoke Therapeutics shares in Q3 2026, an estimated $65.6K.
- Stoke Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #3219 holding.
- JP Morgan Chase first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 29 quarters since.
- JP Morgan Chase's Stoke Therapeutics position peaked at $8.82M in Q4 2025.
- 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.